Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Minerva Neurosciences, Inc.NERV · Entity 6245 | Director | August 03, 2026 | August 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Minerva Neurosciences, Inc.
Report date August 03, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.97 · Expires 2036-08-02 | Direct | 12,147 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 12,147 · Balance 12,147 F1: 25% of the option shall vest on November 14, 2026; an additional 45% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the option shall vest on November 14, 2026; an additional 45% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 3, 2026 22:05 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 12,147 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0002095703-26-000006 · form4-08032026_100811.xml · derivative · entry 1 Kaul Inderjit · CIK 0002095703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,147 Underlying: Common Stock · 12,147 shares Expires 2036-08-02 F1 · derivative.exercise_date: 25% of the option shall vest on November 14, 2026; an additional 45% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 22:00 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0002095703-26-000004 · form4-06052026_060605.xml · derivative · entry 1 Kaul Inderjit · CIK 0002095703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-06-02 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 3, 2026 and an additional 1/4 vesting every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 20:15 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 12,169 | $0.00 Strike: $6.03 | $0.00 |
DisclosureSEC source: 0002095703-26-000002 · form4-04012026_040401.xml · derivative · entry 1 Kaul Inderjit · CIK 0002095703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,169 Underlying: Common Stock · 12,169 shares Expires 2036-03-30 F1 · derivative.exercise_date: 25% of the option shall vest on November 14, 2026; an additional 45% of the option shall vest on the tenth day following the date of the Issuer's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the option shall vest on the tenth day following the date of the Issuer's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:15 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 364,504 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0002095703-25-000007 · form4-12232025_041215.xml · derivative · entry 1 Kaul Inderjit · CIK 0002095703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,504 Underlying: Common Stock · 364,504 shares Expires 2035-12-21 F1 · derivative.exercise_date: 25% of the option shall vest on November 14, 2026; an additional 45% of the option shall vest on the tenth day following the date of the Issuer's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the option shall vest on the tenth day following the date of the Issuer's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:49 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 9,500 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0002095703-25-000005 · form4-11182025_091123.xml · derivative · entry 1 Kaul Inderjit · CIK 0002095703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2035-11-13 F1 · derivative.exercise_date: The shares subject to this option vest in equal quarterly installments over three years with the first installment vesting on February 14, 2026, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.